AR044005A1 - Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden - Google Patents
Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprendenInfo
- Publication number
- AR044005A1 AR044005A1 ARP040101187A ARP040101187A AR044005A1 AR 044005 A1 AR044005 A1 AR 044005A1 AR P040101187 A ARP040101187 A AR P040101187A AR P040101187 A ARP040101187 A AR P040101187A AR 044005 A1 AR044005 A1 AR 044005A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- nr3r4
- cyano
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229940126601 medicinal product Drugs 0.000 title 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 229910052739 hydrogen Inorganic materials 0.000 abstract 8
- 239000001257 hydrogen Substances 0.000 abstract 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 6
- 150000002431 hydrogen Chemical group 0.000 abstract 6
- -1 nitro, hydroxy Chemical group 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 229910052757 nitrogen Chemical group 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 abstract 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 abstract 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 2
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
Abstract
Compuestos bicíclicos de fórmula (1) que incluye estereoisómeros, profármacos y sales o solvatos farmacéuticamente aceptables de los dichos compuestos, en la cual: la línea de trazos representa un doble enlace; R es arilo o heteroarilo, cada uno de los cuales puede estar sustituido con 1 a 4 grupos J seleccionados de: halógeno, alquilo C1-6, alcoxi C1-6, halo alquilo (C1-6), alquenilo C2-6, alquinilo C2-6, halo alcoxi (C1-6), -C(O)R2, nitro, hidroxi, -NR3R4, ciano o un grupo Z; R1 es hidrógeno, cicloalquilo C3-7, alquilo C1-6, alcoxi C1-6, tioalquilo C1-6, alquenilo C2-6, alquinilo C2-6, halo alquilo (C1-6), halo alcoxi (C1-6), halógeno, NR3R4 o ciano; R2 es un alquilo C1-4, -OR3 o -NR3R4; R3 es hidrógeno o alquilo C1-6; R4 es hidrógeno o alquilo C1-6; R5 es un alquilo C1-6, halo alquilo C1-6, alcoxi C1-6, halo alcoxi (C1-6), cicloalquilo C3-7, hidroxi, halógeno, nitro, ciano, -NR3R4; -C(O)R2; R6 es un alquilo C1-6, halo alquilo C1-6, alcoxi C1-6, halo alcoxi (C1-6), cicloalquilo C3-7, hidroxi, halógeno, nitro, ciano, -NR3R4; -C(O)R2; R7 es hidrógeno, alquilo C1-6, halógeno o halo alquilo (C1-6); R8 es hidrógeno, cicloalquilo C3-7, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, NR3R4 o ciano; R9 es hidrógeno, cicloalquilo C3-7, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, NR3R4 o ciano; R10 es hidrógeno, cicloalquilo C3-7, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, NR3R4 o ciano; R11 es hidrógeno, cicloalquilo C3-7, alquilo C1-6, alquenilo C2-6, alquinilo C2-6, NR3R4 o ciano; R12 es R3 o -C(O)R2; D es CR8R9 o es CR8 cuando forma un doble enlace con G; G es CR10R11 o es CR10 cuando forma un doble enlace con D o es CR10 cuando forma un doble enlace con X cuando X es carbono; X es carbono o nitrógeno; Y es nitrógeno o -CR7; W es un anillo de 4-8 miembros que puede estar saturado o que puede contener uno o tres dobles enlaces, y en el cual: un átomo de carbono es reemplazado con un carbonilo o S(O)m; y C1-4 pueden estar opcionalmente reemplazados con oxígeno, nitrógeno o NR12, S(O)m, carbonilo, y dicho anillo puede estar adicionalmente sustituido con 1 a 8 grupos R6; Z es un heterociclo de 5-6 miembros, que puede estar sustituido con 1 a 8 grupos R5 o un anillo fenilo que puede estar sustituido con 1 a 4 grupos R5; m es un número entero de 0 a 2. Procedimientos para su preparación, composiciones farmacéuticas que los contienen y a su uso en el tratamiento de trastornos intermediados por el factor liberador de corticotropina (CRF) tales como depresión, ansiedad, IBS (enfermedad de intestino irritable) e IBD (enfermedad inflamatoria del intestino).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0308208.8A GB0308208D0 (en) | 2003-04-09 | 2003-04-09 | Chemical compounds |
US48532203P | 2003-07-07 | 2003-07-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR044005A1 true AR044005A1 (es) | 2005-08-24 |
Family
ID=33312357
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP040101187A AR044005A1 (es) | 2003-04-09 | 2004-04-07 | Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden |
Country Status (21)
Country | Link |
---|---|
US (2) | US7427630B2 (es) |
EP (3) | EP1611133B1 (es) |
JP (2) | JP4866722B2 (es) |
KR (1) | KR20060021826A (es) |
CN (1) | CN1805958A (es) |
AR (1) | AR044005A1 (es) |
AT (2) | ATE473226T1 (es) |
AU (1) | AU2004232551C1 (es) |
BR (1) | BRPI0409117A (es) |
CA (1) | CA2521929C (es) |
DE (2) | DE602004027998D1 (es) |
GB (1) | GB0308208D0 (es) |
IS (1) | IS8119A (es) |
MA (1) | MA27796A1 (es) |
MX (1) | MXPA05010874A (es) |
NO (1) | NO20055238L (es) |
NZ (1) | NZ542780A (es) |
PL (1) | PL378755A1 (es) |
RU (1) | RU2382785C2 (es) |
TW (1) | TW200508232A (es) |
WO (2) | WO2004094420A1 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0117396D0 (en) | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
DK1668014T3 (da) | 2003-09-17 | 2009-04-20 | Janssen Pharmaceutica Nv | Kondenserede heterocykliske forbindelser som serotoninreceptormodulatorer |
MY143499A (en) * | 2003-12-22 | 2011-05-31 | Sb Pharmco Inc | Crf receptor antagonist and methods relating thereto |
WO2005103690A2 (en) * | 2004-04-24 | 2005-11-03 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2) |
GB0519957D0 (en) * | 2005-09-30 | 2005-11-09 | Sb Pharmco Inc | Chemical compound |
JP2008517060A (ja) * | 2004-10-19 | 2008-05-22 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Crf受容体アンタゴニストおよびその製法 |
GB0507198D0 (en) * | 2005-04-08 | 2005-05-18 | Sb Pharmco Inc | Process for preparing bicyclic compounds |
GB0507195D0 (en) * | 2005-04-08 | 2005-05-18 | Sb Pharmco Inc | Process for preparing bicyclic compounds |
US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
US8088779B2 (en) * | 2005-09-30 | 2012-01-03 | Smithkline Beecham (Cork) Limited | Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
DE602007011628D1 (de) | 2006-07-06 | 2011-02-10 | Array Biopharma Inc | Dihydrofuropyrimidine als akt-proteinkinaseinhibitoren |
ATE532789T1 (de) | 2006-07-06 | 2011-11-15 | Array Biopharma Inc | Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren |
PL2049500T3 (pl) * | 2006-07-06 | 2012-02-29 | Array Biopharma Inc | Cyklopenta[d]pirymidyny jako inhibitory kinaz białkowych AKT |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8377937B2 (en) | 2007-07-05 | 2013-02-19 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
CN103396409B (zh) | 2007-07-05 | 2015-03-11 | 阵列生物制药公司 | 作为akt蛋白激酶抑制剂的嘧啶基环戊烷 |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
US20090118276A1 (en) * | 2007-11-02 | 2009-05-07 | Wyeth | Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors |
US8835434B2 (en) * | 2008-01-09 | 2014-09-16 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US8853216B2 (en) * | 2008-01-09 | 2014-10-07 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as AKT protein kinase inhibitor |
GEP20125637B (en) * | 2008-01-22 | 2012-09-10 | Takeda Pharmaceutical | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them |
MX2010008745A (es) * | 2008-02-28 | 2010-08-30 | Nippon Shinyaku Co Ltd | Inhibidor de fibrosis. |
CL2009001152A1 (es) * | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
JP6147246B2 (ja) | 2011-04-01 | 2017-06-14 | ジェネンテック, インコーポレイテッド | Akt及びmek阻害剤化合物の組み合わせ、及び使用方法 |
BR112013025353A8 (pt) | 2011-04-01 | 2018-01-02 | Genentech Inc | combinação de a) um composto de fórmula ia, composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, método para tratamento de um distúrbio hiperproliferativo em um mamífero, uso de um composto de fórmula ia ou um sal farmaceuticamente aceitável do mesmo, kit e produto |
GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
JP2015516979A (ja) * | 2012-04-23 | 2015-06-18 | ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーHolsboermaschmeyer Neurochemie Gmbh | Crh過剰活性を有する患者の治療に用いるためのcrhr1アンタゴニスト |
EP3822273B1 (en) | 2012-06-13 | 2024-04-10 | Incyte Holdings Corporation | Substituted tricyclic compounds as fgfr inhibitors |
GB201210686D0 (en) | 2012-06-15 | 2012-08-01 | Holsboermaschmeyer Neurochemie Gmbh | V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
TWI649318B (zh) | 2013-04-19 | 2019-02-01 | 英塞特控股公司 | 作為fgfr抑制劑之雙環雜環 |
GB201310782D0 (en) | 2013-06-17 | 2013-07-31 | Max Planck Innovation Gmbh | Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
PE20171514A1 (es) | 2015-02-20 | 2017-10-20 | Incyte Corp | Heterociclos biciclicos como inhibidores de fgfr |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
CR20200591A (es) | 2018-05-04 | 2021-03-31 | Incyte Corp | Sales de un inhibidor de fgfr |
AU2019262195A1 (en) | 2018-05-04 | 2020-12-24 | Incyte Corporation | Solid forms of an FGFR inhibitor and processes for preparing the same |
WO2020185532A1 (en) | 2019-03-08 | 2020-09-17 | Incyte Corporation | Methods of treating cancer with an fgfr inhibitor |
US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
MX2022004513A (es) | 2019-10-14 | 2022-07-19 | Incyte Corp | Heterociclos biciclicos como inhibidores de los receptores del factor de crecimiento de fibroblastos (fgfr). |
US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
EP4069696A1 (en) | 2019-12-04 | 2022-10-12 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
PE20221504A1 (es) | 2019-12-04 | 2022-09-30 | Incyte Corp | Derivados de un inhibidor de fgfr |
WO2022261160A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
WO2023166067A1 (en) | 2022-03-02 | 2023-09-07 | Syngenta Crop Protection Ag | Microbiocidal pyridazinone amide derivatives |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5169857A (en) * | 1988-01-20 | 1992-12-08 | Bayer Aktiengesellschaft | 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis |
NO177005C (no) | 1988-01-20 | 1995-07-05 | Bayer Ag | Analogifremgangsmåte for fremstilling av substituerte pyridiner, samt mellomprodukter til bruk ved fremstillingen |
GB8810553D0 (en) | 1988-05-05 | 1988-06-08 | Smith D W | Integrated hydraulic pedal |
GB2248618B (en) | 1988-06-17 | 1993-01-06 | Wyeth John & Brother Ltd | Process for preparing pyridine derivatives |
ES2087916T3 (es) | 1989-10-11 | 1996-08-01 | Teijin Ltd | Derivado de pirimidina biciclico, metodo para producir el mismo, y preparacion farmaceutica que contiene el mismo como ingrediente activo. |
DE4022414A1 (de) | 1990-07-13 | 1992-01-16 | Bayer Ag | Substituierte pyrrolo-pyridine |
AU665184B2 (en) | 1991-01-23 | 1995-12-21 | Gensia, Inc. | Adenosine kinase inhibitors |
GB9125842D0 (en) | 1991-12-04 | 1992-02-05 | Ici Plc | Heterocyclic derivatives |
US5502187A (en) * | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
DE69329574T2 (de) | 1992-04-03 | 2001-05-31 | Upjohn Co | Pharmazeutisch wirksame bicyclisch heterocyclische amine |
JPH0710876A (ja) | 1993-06-24 | 1995-01-13 | Teijin Ltd | 4位に環状アミノ基を有するピロロ[2,3―d]ピリミジン |
EP0723533A1 (en) * | 1993-10-12 | 1996-07-31 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
CN1142817A (zh) | 1993-10-12 | 1997-02-12 | 杜邦麦克制药有限公司 | 1n-烷基-n-芳基嘧啶胺及其衍生物 |
TW574214B (en) * | 1994-06-08 | 2004-02-01 | Pfizer | Corticotropin releasing factor antagonists |
EP0765327B1 (en) | 1994-06-16 | 1999-07-21 | Pfizer Inc. | Pyrazolo and pyrrolopyridines |
EP0729758A3 (en) | 1995-03-02 | 1997-10-29 | Pfizer | Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases |
US6403599B1 (en) | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
US5955613A (en) | 1995-10-13 | 1999-09-21 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel CRF1 specific ligands |
AU738304B2 (en) * | 1995-10-13 | 2001-09-13 | Neurogen Corporation | Certain pyrrolopyridine derivatives; novel CRF 1 specific ligands |
BR9710808A (pt) | 1996-08-06 | 1999-08-17 | Pfizer | Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos |
TW477787B (en) | 1996-08-27 | 2002-03-01 | Pfizer | Pyrido six-membered nitrogen-containing cyclic ring derivatives having corticotropin releasing factor antagonist activity and pharmaceutical composition containing same |
HUP9903965A3 (en) | 1996-08-28 | 2002-02-28 | Pfizer | Substituted 6,5-hetero-bicyclic derivatives |
EP0970082A2 (en) * | 1997-02-18 | 2000-01-12 | Neurocrine Biosciences, Inc. | Biazacyclic crf antagonists |
IL133430A0 (en) | 1997-08-05 | 2001-04-30 | Pfizer Prod Inc | 4-AMINOPYRROLE (3, 2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
WO1999051599A1 (en) * | 1998-04-02 | 1999-10-14 | Neurogen Corporation | Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors |
JPH11335376A (ja) | 1998-05-25 | 1999-12-07 | Taisho Pharmaceut Co Ltd | アリールテトラヒドロピリジン誘導体 |
JP2000086663A (ja) | 1998-09-09 | 2000-03-28 | Taisho Pharmaceut Co Ltd | アリールテトラヒドロピリジン誘導体 |
WO2000058307A2 (en) | 1999-03-11 | 2000-10-05 | Neurogen Corporation | Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
AU4038000A (en) | 1999-03-29 | 2000-10-16 | Neurogen Corporation | 4-substituted quinoline derivatives as gaba receptor ligands |
FR2791675B1 (fr) | 1999-03-30 | 2001-05-04 | Synthelabo | Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique |
EP1040831A3 (en) | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
US6284766B1 (en) | 1999-04-30 | 2001-09-04 | Neurogen Corporation | 9H-pyrimido [4,5-b] indole derivatives: CRF1 specific ligands |
CZ20021086A3 (cs) | 1999-09-30 | 2002-10-16 | Neurogen Corporation | Alkylendiaminem substituované heterocykly |
US6525067B1 (en) * | 1999-11-23 | 2003-02-25 | Pfizer Inc | Substituted heterocyclic derivatives |
AP2002002583A0 (en) | 2000-01-18 | 2002-09-30 | Pfizer Prod Inc | Corticotropin releasing factor antagonists. |
AR028782A1 (es) | 2000-07-05 | 2003-05-21 | Taisho Pharmaceutical Co Ltd | Derivados heterociclicos tetrahidropiridino o piperidino |
AU2001284417A1 (en) | 2000-09-05 | 2002-03-22 | Taisho Pharmaceutical Co. Ltd. | Hair growth stimulants |
GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
CN1649848A (zh) * | 2001-04-30 | 2005-08-03 | 葛兰素集团有限公司 | 作为促肾上腺皮质激素释放因子(crf)拮抗剂的稠合嘧啶衍生物 |
ES2255610T3 (es) | 2001-04-30 | 2006-07-01 | Glaxo Group Limited | Antagonistas de los receptores de crf. |
MXPA03010635A (es) | 2001-05-21 | 2004-12-06 | Sb Pharmco Inc | Derivados de tri- y tetraazaacenaftileno como antagonistas del receptor de crf. |
EP1395591B1 (en) * | 2001-06-12 | 2008-06-04 | Glaxo Group Limited | Corticotropin releasing factor antagonists |
US7273871B2 (en) | 2001-07-17 | 2007-09-25 | Sb Pharmco Puerto Rico Inc. | Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists |
GB0117396D0 (en) * | 2001-07-17 | 2001-09-05 | Glaxo Group Ltd | Chemical compounds |
US7115741B2 (en) | 2001-09-06 | 2006-10-03 | Levy Daniel E | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds |
SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
WO2004062665A1 (en) | 2003-01-16 | 2004-07-29 | Sb Pharmco Puerto Rico Inc | Heteroaryl- substituted pyrrolo` 2, 3- b! pyridine derivatives as crf receptor antagonists |
WO2004087140A1 (en) * | 2003-03-27 | 2004-10-14 | Boehringer Ingelheim International Gmbh | Antiviral combination of a dipyridodiazepinone and a further antiretroviral compound |
US20070021429A1 (en) * | 2003-04-09 | 2007-01-25 | Yves St-Denis | Condensed n-heterocyclic compounds and their use as crf receptor antagonists |
US20070293511A1 (en) | 2003-12-22 | 2007-12-20 | Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation | Crf Receptor Antagonists and Methods |
ATE388150T1 (de) | 2003-12-22 | 2008-03-15 | Sb Pharmco Inc | Crf-rezeptorantagonisten und diese betreffende verfahren |
MY143499A (en) | 2003-12-22 | 2011-05-31 | Sb Pharmco Inc | Crf receptor antagonist and methods relating thereto |
-
2003
- 2003-04-09 GB GBGB0308208.8A patent/GB0308208D0/en not_active Ceased
-
2004
- 2004-04-07 CN CNA2004800161898A patent/CN1805958A/zh active Pending
- 2004-04-07 NZ NZ542780A patent/NZ542780A/en unknown
- 2004-04-07 JP JP2006506558A patent/JP4866722B2/ja not_active Expired - Fee Related
- 2004-04-07 EP EP04726237A patent/EP1611133B1/en not_active Expired - Lifetime
- 2004-04-07 TW TW093109539A patent/TW200508232A/zh unknown
- 2004-04-07 MX MXPA05010874A patent/MXPA05010874A/es active IP Right Grant
- 2004-04-07 BR BRPI0409117-5A patent/BRPI0409117A/pt not_active IP Right Cessation
- 2004-04-07 AT AT04726237T patent/ATE473226T1/de not_active IP Right Cessation
- 2004-04-07 AR ARP040101187A patent/AR044005A1/es unknown
- 2004-04-07 KR KR1020057019098A patent/KR20060021826A/ko not_active Application Discontinuation
- 2004-04-07 US US10/552,493 patent/US7427630B2/en not_active Expired - Lifetime
- 2004-04-07 RU RU2005134652/04A patent/RU2382785C2/ru not_active IP Right Cessation
- 2004-04-07 DE DE602004027998T patent/DE602004027998D1/de not_active Expired - Lifetime
- 2004-04-07 CA CA2521929A patent/CA2521929C/en not_active Expired - Fee Related
- 2004-04-07 WO PCT/IB2004/001350 patent/WO2004094420A1/en active Application Filing
- 2004-04-07 PL PL378755A patent/PL378755A1/pl not_active Application Discontinuation
- 2004-04-07 EP EP08169936A patent/EP2186813A1/en not_active Withdrawn
- 2004-04-07 AU AU2004232551A patent/AU2004232551C1/en not_active Ceased
- 2004-04-08 DE DE602004027900T patent/DE602004027900D1/de not_active Expired - Lifetime
- 2004-04-08 JP JP2006506536A patent/JP2006522798A/ja active Pending
- 2004-04-08 AT AT04726587T patent/ATE472547T1/de not_active IP Right Cessation
- 2004-04-08 EP EP04726587A patent/EP1618107B1/en not_active Expired - Lifetime
- 2004-04-08 WO PCT/IB2004/001283 patent/WO2004094419A1/en active Application Filing
-
2005
- 2005-11-08 MA MA28585A patent/MA27796A1/fr unknown
- 2005-11-08 NO NO20055238A patent/NO20055238L/no not_active Application Discontinuation
- 2005-11-08 IS IS8119A patent/IS8119A/is unknown
-
2007
- 2007-10-31 US US11/931,313 patent/US20110172255A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR044005A1 (es) | Compuestos biciclicos, procedimiento para su preparacion, su uso para preparar un medicamento y composiciones farmaceuticas que los comprenden | |
AR071856A1 (es) | Derivados de indazoles sustituidos con fenilo o piridinilo, un proceso para su preparacion, una composicion farmaceutica que los comprende y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por el receptor de glucocorticoides. | |
AR033295A1 (es) | Compuestos biciclicos de pirimidina, proceso para su obtencion, uso de los mismos para la preparacion de una composicion farmaceutica y dicha composicion farmaceutica | |
AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
AR044402A1 (es) | Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen. | |
AR065622A1 (es) | Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona | |
AR087711A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y uso de los mismos para el tratamiento de trastornos neurodegenerativos | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
AR059184A1 (es) | Derivados de sulfonamidas, su preparacion y su aplicacion en tarapeutica | |
AR059328A1 (es) | Derivados de antranilamida-2-amino-heteroareno-carboxamida, un proceso para su obtencion, composiciones farmaceuticas que los contienen y el uso de estos compuestos para la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por cetp | |
AR056979A1 (es) | Derivados de dihidrobenzofuranos y usos de los mismos | |
AR066155A1 (es) | Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia | |
PE20151860A1 (es) | Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhidores de la phd | |
AR078164A1 (es) | Derivados de isoxazolidina, proceso para preparar dichos compuestos y composiciones farmaceuticas que los comprenden | |
AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
RU2014121205A (ru) | Производные азолов | |
RS54833B1 (sr) | Novi hiralni n-acil-5,6,7, (8-supstituisan)-tetrahidro-[1,2,4]triazolo [4,3-a]pirazini kao selektivni antagonisti nk-3 receptora, farmaceutsko jedinjenje, i postupci za upotrebu u nk-3 receptorom posredovanim poremećajima | |
AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
AR055171A1 (es) | Derivados de carboxamida como antagonistas del receptor muscarinico | |
AR092288A1 (es) | Ligandos del receptor ep1 | |
AR075975A1 (es) | Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3 | |
AR067869A1 (es) | Derivados de piridina y pirimidina | |
AR075531A1 (es) | Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros | |
MY194004A (en) | 4 -substituted benzoxaborole compounds and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |